Form 4: BridgeBio Pharma Director Andrew Lo Acquires Stock Options

Director Andrew Lo acquired stock options for 26,014 shares of BridgeBio Pharma, Inc. on June 21, 2024.

Summary

• On June 21, 2024, Andrew Lo, a director of BridgeBio Pharma, Inc., acquired stock options for 26,014 shares.
• The exercise price of these options is $27.36.
• The options vest in three equal annual installments starting June 21, 2024, and will be fully vested by June 21, 2027, contingent upon continued service on the board.
• Following the transaction, Andrew Lo directly owns options for 26,014 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is a common practice. It doesn't inherently indicate positive or negative sentiment, but rather provides transparency.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers. This allows investors to monitor insider activity, which can provide insights into management's perspective on the company's prospects.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates